RAC
RACURA ONCOLOGY ORDINARYRacura Oncology Ltd operates as a clinical-stage biopharmaceutical company in Australia. It develops RC220, a formulation of (E,E)-bisantrene, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; Phase Ia/b clinical trial for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer; and Phase Ia/b clinical trial for the treatment of solid tumor cancers. The company was formerly known as Race Oncology Limited and changed its name to Racura Oncology Ltd in December 2025. Racura Oncology Ltd was incorporated in 2011 and is headquartered in Sydney, Australia.
RAC
RAC
RACURA ONCOLOGY ORDINARY
Racura Oncology Ltd operates as a clinical-stage biopharmaceutical company in Australia. It develops RC220, a formulation of (E,E)-bisantrene, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; Phase Ia/b clinical trial for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer; and Phase Ia/b clinical trial for the treatment of solid tumor cancers.
Fundamentals
Historical Data63 days
| Date | Short % | Gross Short |
|---|---|---|
| 28 Aug | — | — |
| 27 Aug | — | — |
| 26 Aug | — | — |
| 25 Aug | 0.01% | — |
| 24 Aug | 0.01% | — |
| 21 Aug | 0.01% | — |
| 20 Aug | 0.01% | — |
| 19 Aug | 0.01% | — |
| 18 Aug | 0.01% | — |
| 17 Aug | 0.01% | — |
| 14 Aug | 0.01% | — |
| 13 Aug | 0.01% | — |
Racura Oncology (RAC) Short Interest Summary
Racura Oncology (RAC) currently has 0.01% of its shares sold short (19 thousand shares, worth approximately $42K), based on ASIC short position data reported on 25 August 2026 (T+4 reporting lag). That makes RAC the #580 most shorted stock on the ASX most shorted list. Short interest in RAC is up 0.00% over the past week and up 0.00% over the past month. RAC is part of the Health Care sector on the ASX.
Recent RAC Short Position History
| Date | Short % | Short Shares | Close Price |
|---|---|---|---|
| 25 Aug 2026 | 0.01% | 0.0M | $2.12 |
| 24 Aug 2026 | 0.01% | 0.0M | $2.10 |
| 21 Aug 2026 | 0.01% | 0.0M | $2.10 |
| 20 Aug 2026 | 0.01% | 0.0M | $2.10 |
| 19 Aug 2026 | 0.01% | 0.0M | $2.12 |
| 18 Aug 2026 | 0.01% | 0.0M | $2.12 |
| 17 Aug 2026 | 0.01% | 0.0M | $2.09 |
| 14 Aug 2026 | 0.01% | 0.0M | $2.00 |
| 13 Aug 2026 | 0.01% | 0.0M | $2.01 |
| 12 Aug 2026 | 0.01% | 0.0M | $2.05 |
RAC Short Selling — Frequently Asked Questions
What is Racura Oncology (RAC)'s current short interest?
Racura Oncology (RAC) currently has a short interest of 0.01% of total shares outstanding. This means 0.01% of RAC's shares have been sold short by investors who expect the price to decline. This data is sourced from ASIC reports and updated daily.
Is RAC heavily shorted on the ASX?
RAC has a relatively low short interest of 0.01%. Short interest below 5% generally suggests limited bearish sentiment from short sellers.
What does short interest mean for RAC investors?
Short interest in RAC shows the percentage of shares investors have borrowed and sold, betting the price will fall. At 0.01%, RAC's short interest is at a low level. See our short squeeze candidates and days to cover analysis for more context.
Where does this RAC short data come from?
Short position data is published by ASIC with a four trading day delay (T+4) and covers reported short positions as a percentage of total shares on issue. ASX Short Data also tracks daily gross short sales (T+1), securities lending, and director trades for RAC.